| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.36▼ | 2.36▼ | 2.36▼ | 2.35▼ | 2.39▼ |
| MA10 | 2.37▼ | 2.38▼ | 2.37▼ | 2.37▼ | 2.46▼ |
| MA20 | 2.38▼ | 2.39▼ | 2.38▼ | 2.44▼ | 2.45▼ |
| MA50 | 2.40▼ | 2.39▼ | 2.38▼ | 2.48▼ | 2.72▼ |
| MA100 | 2.39▼ | 2.41▼ | 2.48▼ | 2.47▼ | 4.46▼ |
| MA200 | 2.43▼ | 2.50▼ | 2.48▼ | 2.70▼ | 4.52▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.006▼ | -0.007▼ | -0.006▼ | -0.009▼ | 0.018▲ |
| RSI | 37.230▼ | 38.816▼ | 40.391▼ | 42.590▼ | 41.724▼ |
| STOCH | 40.100 | 42.184 | 32.431 | 38.241 | 37.385 |
| WILL %R | -89.474▼ | -89.474▼ | -94.444▼ | -80.000▼ | -87.223▼ |
| CCI | -184.863▼ | -170.713▼ | -145.248▼ | -159.789▼ | -122.035▼ |
|
Monday, May 22, 2023 07:00 AM
AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 23/02/26 | 2.32 | 2.32 | 2.32 | 2.32 | 0 |
| 20/02/26 | 2.38 | 2.448 | 2.30 | 2.31 | 22,771 |
| 19/02/26 | 2.41 | 2.41 | 2.34 | 2.38 | 21,598 |
| 18/02/26 | 2.40 | 2.415 | 2.35 | 2.41 | 7,788 |
| 17/02/26 | 2.44 | 2.46 | 2.34 | 2.34 | 8,805 |
| 13/02/26 | 2.39 | 2.48 | 2.39 | 2.45 | 45,553 |
| 12/02/26 | 2.39 | 2.44 | 2.36 | 2.37 | 10,568 |
| 11/02/26 | 2.40 | 2.4199 | 2.37 | 2.37 | 13,455 |
| 10/02/26 | 2.36 | 2.45 | 2.36 | 2.42 | 35,556 |
| 09/02/26 | 2.35 | 2.38 | 2.30 | 2.31 | 23,682 |
|
|
||||
|
|
||||
|
|